News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
173,042 Results
Type
Article (7386)
Company Profile (53)
Press Release (165603)
Section
Business (56280)
Career Advice (294)
Deals (10521)
Drug Delivery (19)
Drug Development (14233)
Employer Resources (22)
FDA (3871)
Job Trends (4123)
News (85459)
Policy (6103)
Tag
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (1)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (1)
2024 Biotech Bay Standard (9)
2024 Biotech Beach Digital (2)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (1)
2026 BioCapital Standard (1)
2026 Genetown Elite (1)
Academia (886)
Academic (1)
Adcomms (2)
Allergies (13)
Alliances (18347)
ALS (16)
Alzheimer's disease (307)
Antibody-drug conjugate (ADC) (14)
Approvals (3885)
Artificial intelligence (147)
Autoimmune disease (4)
Automation (10)
Bankruptcy (37)
Best Places to Work (3662)
BIOSECURE Act (1)
Biosimilars (20)
Biotechnology (35)
Bladder cancer (14)
Brain cancer (9)
Breast cancer (90)
Cancer (625)
Cardiovascular disease (21)
Career advice (261)
Career pathing (6)
CAR-T (29)
Cell therapy (100)
Cervical cancer (3)
Clinical research (10820)
Collaboration (335)
Compensation (35)
Complete response letters (2)
COVID-19 (554)
CRISPR (12)
C-suite (69)
Cystic fibrosis (15)
Data (509)
Decentralized trials (1)
Denatured (4)
Depression (7)
Diabetes (55)
Diagnostics (3730)
Digital health (11)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (45)
Drug pricing (9)
Drug shortages (5)
Duchenne muscular dystrophy (11)
Earnings (17529)
Editorial (3)
Employer branding (4)
Employer resources (19)
Events (22164)
Executive appointments (231)
FDA (4167)
Featured Employer (25)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (175)
Gene editing (34)
Generative AI (13)
Gene therapy (61)
GLP-1 (110)
Government (836)
Guidances (21)
Healthcare (5731)
Huntington's disease (1)
Immunology and inflammation (16)
Indications (11)
Infectious disease (577)
Inflammatory bowel disease (29)
Influenza (9)
Intellectual property (16)
Interviews (38)
IPO (3515)
IRA (2)
Job creations (559)
Job search strategy (229)
Kidney cancer (2)
Layoffs (46)
Leadership (1)
Legal (1068)
Liver cancer (16)
Lung cancer (85)
Lymphoma (41)
Machine learning (2)
Management (8)
Manufacturing (98)
MASH (5)
Medical device (3667)
Medtech (3669)
Mergers & acquisitions (7219)
Metabolic disorders (102)
Multiple sclerosis (18)
Neurodegenerative disease (9)
Neuropsychiatric disorders (2)
Neuroscience (399)
NextGen: Class of 2025 (1820)
Non-profit (1077)
Northern California (627)
Now hiring (6)
Obesity (42)
Opinion (34)
Ovarian cancer (15)
Pain (14)
Pancreatic cancer (19)
Parkinson's disease (33)
Partnered (5)
Patents (33)
Patient recruitment (28)
Peanut (9)
People (17500)
Pharmaceutical (15)
Pharmacy benefit managers (7)
Phase I (3932)
Phase II (4636)
Phase III (3493)
Pipeline (233)
Podcasts (7)
Policy (8)
Postmarket research (361)
Preclinical (2268)
Press Release (42)
Prostate cancer (26)
Psychedelics (6)
Radiopharmaceuticals (92)
Rare diseases (49)
Real estate (1663)
Recruiting (8)
Regulatory (4599)
Reports (20)
Research institute (1019)
Resumes & cover letters (41)
RNA editing (1)
RSV (1)
Schizophrenia (2)
Series A (36)
Series B (18)
Service/supplier (1)
Sickle cell disease (11)
Southern California (410)
Spinal muscular atrophy (26)
Sponsored (10)
Startups (929)
State (1)
Stomach cancer (1)
Supply chain (9)
The Weekly (3)
United States (5249)
Vaccines (78)
Venture capitalists (5)
Webinars (2)
Weight loss (21)
Women's health (4)
Worklife (1)
Date
Today (52)
Last 7 days (195)
Last 30 days (813)
Last 365 days (9304)
2025 (2154)
2024 (9516)
2023 (11166)
2022 (14149)
2021 (15494)
2020 (15459)
2019 (13996)
2018 (10470)
2017 (8926)
2016 (8400)
2015 (9503)
2014 (6669)
2013 (5529)
2012 (6050)
2011 (6509)
2010 (5375)
Location
Africa (159)
Alabama (25)
Alaska (1)
Arizona (42)
Arkansas (5)
Asia (11827)
Australia (1427)
California (1288)
Canada (436)
China (173)
Colorado (81)
Connecticut (46)
Delaware (27)
Europe (24426)
Florida (214)
Georgia (38)
Idaho (13)
Illinois (157)
India (18)
Indiana (113)
Iowa (3)
Japan (35)
Kansas (17)
Kentucky (5)
Louisiana (4)
Maine (11)
Maryland (218)
Massachusetts (932)
Michigan (71)
Minnesota (106)
Mississippi (1)
Missouri (27)
Montana (15)
Nebraska (9)
Nevada (18)
New Hampshire (19)
New Jersey (449)
New Mexico (17)
New York (357)
North Carolina (282)
North Dakota (5)
Northern California (627)
Ohio (82)
Oklahoma (8)
Oregon (10)
Pennsylvania (224)
Puerto Rico (2)
Rhode Island (6)
South America (268)
South Carolina (7)
South Dakota (1)
Southern California (410)
Tennessee (47)
Texas (231)
Utah (76)
Virginia (25)
Washington D.C. (13)
Washington State (102)
West Virginia (1)
Wisconsin (16)
173,042 Results for "integral molecular".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Lilly Hops On Hot Molecular Glue Train With $1.2B+ Magnet Deal
The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and Novartis.
February 28, 2025
·
2 min read
·
Tristan Manalac
Business
Integrated DNA Technologies and Molecular Health Ink Commercial Partnership
Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities.
May 15, 2024
·
6 min read
Pharm Country
Integral Molecular Launches Virus Neutralization Assay Services to Drive Antiviral Discovery
Integral Molecular announces the launch of its Virus Neutralization Assay Services enabling researchers to rapidly obtain high-quality data to advance their vaccines and therapeutic antibodies.
April 16, 2024
·
2 min read
Pharm Country
Integral Molecular Achieves ISO 9001 Certification for its Membrane Proteome Array Service
Integral Molecular proudly announces the achievement of IS0 9001 certification for the quality systems and processes used in its Membrane Proteome Array™ specificity testing services.
March 27, 2024
·
2 min read
Drug Development
Molecular Glue Degraders at Inflection Point as Pharma Dives In
Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.
December 16, 2024
·
6 min read
·
Kate Goodwin
Business
Integral Molecular Enters Into Exclusive Antibody License With Seismic Therapeutic
Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets, announced today that it has entered into an antibody license agreement with Seismic Therapeutic.
January 4, 2024
·
2 min read
Earnings
Biogen Tops Wall Street Expectations for Leqembi, Inks Molecular Glue Deal
Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with Neomorph to discover and develop molecular glue degraders.
October 30, 2024
·
2 min read
·
Heather McKenzie
Collaboration
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.
October 28, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
March 3, 2025
·
5 min read
Pharm Country
Integral Molecular Launches TiterSafe™ Influenza Virus-Like Particles for Safe and Convenient Vaccine Testing
Integral Molecular, a leading provider of reagents for vaccine evaluation, announces the launch of TiterSafe™ influenza virus-like particles, an off-the-shelf virus-alternative for key experiments in testing influenza vaccines.
November 7, 2023
·
2 min read
1 of 17,305
Next
